Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32
Open Access
- 17 January 2018
- journal article
- research article
- Published by Elsevier BV in Journal of Allergy and Clinical Immunology
- Vol. 142 (2), 497-509.e9
- https://doi.org/10.1016/j.jaci.2017.09.052
Abstract
No abstract availableFunding Information
- Megagrant of the Government of the Russian Federation (14.W03.31.0024)
This publication has 40 references indexed in Scilit:
- A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS–Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 PhenotypeThe Journal of Immunology, 2013
- Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptidesClinical and Translational Allergy, 2013
- Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodiesJournal of Allergy and Clinical Immunology, 2011
- Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergyJournal of Allergy and Clinical Immunology, 2011
- Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivativesClinical & Experimental Allergy, 2008
- Original article: Visual analog scales can assess the severity of rhinitis graded according to ARIA guidelinesAllergy, 2007
- Immunological mechanisms of allergen-specific immunotherapyNature Reviews Immunology, 2006
- Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1The FASEB Journal, 2001
- INDUCTION OF TH1 AND TH2 CD4+T CELL RESPONSES:The Alternative ApproachesAnnual Review of Immunology, 1997
- Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.JCI Insight, 1997